Free Trial

Trevi Therapeutics (TRVI) Competitors

Trevi Therapeutics logo
$10.36 -0.27 (-2.54%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$10.44 +0.09 (+0.82%)
As of 10/17/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRVI vs. ACLX, AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, and LNTH

Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Trevi Therapeutics vs. Its Competitors

Trevi Therapeutics (NASDAQ:TRVI) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Trevi Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

In the previous week, Arcellx had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Arcellx and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.65 beat Arcellx's score of -0.26 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trevi Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcellx
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Arcellx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Trevi Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A-$47.91M-$0.42-24.67
Arcellx$56.98M84.67-$107.35M-$3.42-25.44

Trevi Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Trevi Therapeutics' return on equity of -41.44% beat Arcellx's return on equity.

Company Net Margins Return on Equity Return on Assets
Trevi TherapeuticsN/A -41.44% -38.21%
Arcellx -329.93%-43.04%-27.41%

Trevi Therapeutics presently has a consensus price target of $21.75, indicating a potential upside of 109.94%. Arcellx has a consensus price target of $113.08, indicating a potential upside of 30.00%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Arcellx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Arcellx
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Trevi Therapeutics beats Arcellx on 10 of the 15 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVI vs. The Competition

MetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.29B$3.39B$6.09B$10.49B
Dividend YieldN/A2.28%5.73%4.81%
P/E Ratio-24.6722.4484.5227.09
Price / SalesN/A429.44568.62202.80
Price / CashN/A46.5937.1661.22
Price / Book7.9710.4112.246.52
Net Income-$47.91M-$52.47M$3.32B$276.75M
7 Day Performance3.70%2.32%1.25%1.97%
1 Month Performance21.31%11.14%6.28%2.23%
1 Year Performance232.05%11.15%59.92%35.58%

Trevi Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVI
Trevi Therapeutics
2.6644 of 5 stars
$10.36
-2.5%
$21.75
+109.9%
+232.1%$1.29BN/A-24.6720Gap Down
ACLX
Arcellx
2.3257 of 5 stars
$86.23
-0.7%
$112.69
+30.7%
-8.7%$4.81B$107.94M-25.2180Analyst Forecast
AKRO
Akero Therapeutics
3.6671 of 5 stars
$53.66
-0.4%
$73.38
+36.7%
+74.7%$4.31BN/A-26.8330Insider Trade
CRNX
Crinetics Pharmaceuticals
4.2868 of 5 stars
$44.43
-1.1%
$74.45
+67.6%
-29.4%$4.23B$1.04M-10.81210
MENS
Jyong Biotech
N/A$55.70
+0.8%
N/AN/A$4.20BN/A0.0031
NAMS
NewAmsterdam Pharma
2.9523 of 5 stars
$37.15
+0.3%
$42.00
+13.1%
+91.3%$4.17B$45.56M-22.934News Coverage
Analyst Forecast
High Trading Volume
KYMR
Kymera Therapeutics
1.0196 of 5 stars
$59.89
+4.7%
$61.26
+2.3%
+29.4%$4.09B$47.07M-17.26170Analyst Forecast
Insider Trade
SRRK
Scholar Rock
4.5442 of 5 stars
$34.28
-13.1%
$47.00
+37.1%
-4.5%$3.79B$33.19M-11.78140Gap Down
High Trading Volume
VKTX
Viking Therapeutics
3.8869 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-48.1%$3.77BN/A-22.1620News Coverage
Upcoming Earnings
Gap Down
MIRM
Mirum Pharmaceuticals
3.5938 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+87.0%$3.65B$336.89M-59.64140Trending News
Analyst Forecast
Analyst Revision
LNTH
Lantheus
4.5387 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-51.9%$3.64B$1.53B14.52700Trending News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:TRVI) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners